Scholarlink

Background <p>Mutations occurring in the Fibroblast Growth Factor Receptor (FGFR3) gene are thought to be associated with the incidence and prognosis of non-muscle invasive bladder tumors (NMIBC). Yet, their prognostic significance in the Tunisian population remains unclear. Herein, we aim to investigate their prognostic impact in NMIBC in terms of recurrence, progression, and survival.</p> Methods and results <p>It is a monocentric retrospective study including 42 NMIBC patients. DNA was isolated from formalin-fixed paraffin-embedded tissue samples. Polymerase Chain Reaction (PCR) followed by Sanger sequencing were performed for a targeted mutations’ screening of the hot-spot regions of the FGFR3 gene (exons 7 and 15). Overall survival (OS) and disease-specific survival (DSS) were estimated by the Kaplan-Meier method and the corresponding curves were compared using log-rank test. Sequencing analysis revealed 15 different mutations in FGFR3 gene across 26 different tumors (68%). Among these, 9 are already reported mutations (S249C, P250R, P250S, H251Q, S249S, S249Y, S249A, T264T, Thr651) and, interestingly, 6 are new variants (P250A, H251L, A257S, P253P, I254V, R618S). FGFR3-mutated NMIBC and wild-type FGFR3 tumors were comparable in terms of clinical and endoscopic presentation. The presence of FGFR3 mutations was not statistically correlated to a decrease in OS and DSS. The main factors correlated with their presence were the solid appearance of the tumor (<i>p</i> = 0.04), the presence of tumor calcifications (<i>p</i> = 0.04), and tumor stage (<i>p</i> = 0.04).</p> Conclusion <p>FGFR3 mutations were common in our series. These variations seem to be a favorable prognostic factor for NMIBC in our population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FGFR3 gene mutations screening in non-muscle invasive bladder cancer (NMIBC) in the Tunisian population

  • 期刊论文

  • 发表日期：

    2025年3月26日

查看全文
  • Bilel Saidani,
  • Nouha Setti Boubaker,
  • Marouen Chakroun,
  • Haroun Ayed,
  • Meriem Ksontini,
  • Zeineb Naimi,
  • Khedija Meddeb,
  • Ahmed Saadi,
  • Soumaya Rammeh,
  • Mohamed Riadh Ben Slama

摘要

Background

Mutations occurring in the Fibroblast Growth Factor Receptor (FGFR3) gene are thought to be associated with the incidence and prognosis of non-muscle invasive bladder tumors (NMIBC). Yet, their prognostic significance in the Tunisian population remains unclear. Herein, we aim to investigate their prognostic impact in NMIBC in terms of recurrence, progression, and survival.

Methods and results

It is a monocentric retrospective study including 42 NMIBC patients. DNA was isolated from formalin-fixed paraffin-embedded tissue samples. Polymerase Chain Reaction (PCR) followed by Sanger sequencing were performed for a targeted mutations’ screening of the hot-spot regions of the FGFR3 gene (exons 7 and 15). Overall survival (OS) and disease-specific survival (DSS) were estimated by the Kaplan-Meier method and the corresponding curves were compared using log-rank test. Sequencing analysis revealed 15 different mutations in FGFR3 gene across 26 different tumors (68%). Among these, 9 are already reported mutations (S249C, P250R, P250S, H251Q, S249S, S249Y, S249A, T264T, Thr651) and, interestingly, 6 are new variants (P250A, H251L, A257S, P253P, I254V, R618S). FGFR3-mutated NMIBC and wild-type FGFR3 tumors were comparable in terms of clinical and endoscopic presentation. The presence of FGFR3 mutations was not statistically correlated to a decrease in OS and DSS. The main factors correlated with their presence were the solid appearance of the tumor (p = 0.04), the presence of tumor calcifications (p = 0.04), and tumor stage (p = 0.04).

Conclusion

FGFR3 mutations were common in our series. These variations seem to be a favorable prognostic factor for NMIBC in our population.